Hormonal
Prescription medication-driven weight loss (mdWL) using GLP-1 agonists causes facial aesthetic changes including skin laxity, hollowed cheeks, and pronounced wrinkles, primarily affecting superficial and deep fat pads rather than bone or muscle.
If you are losing weight rapidly with prescription medications like Ozempic or Wegovy, expect changes in your face, such as sagging skin or hollow cheeks, due to fat loss in specific facial layers. This is a common side effect of the medication's mechanism, not a sign of poor health. To manage this, consult an aesthetic provider about timing treatments (like fillers or skin tightening) to coincide with your weight stabilization, rather than during active rapid loss. Avoid terms like 'Ozempic face' and focus on 'mdWL' management to reduce stigma.
Panelists believed that the skin layers most strongly affected by mdWL are the superficial and deep fat pads... Panelists reported that patients who have not yet begun their aesthetic journey after major RWL (e.g., 20+ lbs/10 + kg) complain most of skin that feels loose or saggy, hollowed- out cheeks, sunken areas beneath the eyes, and more pronounced lines that run between the nose and mouth.
Why this rating
Based on expert consensus (Delphi study) and patient interviews, not randomized controlled trials of the aesthetic outcomes themselves.
Source
Consensus Statements on Managing Aesthetic Needs in Prescription Medication‐Driven Weight Loss Patients: An International, Multidisciplinary Delphi Study
Andreas Nikolis et al. · Journal of Cosmetic Dermatology · 2025
DOI 10.1111/jocd.70094
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →